Cardiac Calcium Channel Blocker Therapy represents a fundamental aspect of cardiovascular care, offering a targeted approach to managing heart-related conditions. These blockers, recognized as calcium antagonists, exert their therapeutic effects by impeding the entry of calcium ions into cardiac muscle cells. This mechanism proves particularly valuable in addressing diverse cardiovascular issues, ranging from hypertension and angina to specific arrhythmias. By facilitating the dilation of blood vessels and promoting cardiac relaxation, calcium channel blockers contribute to improved blood flow and reduced strain on the heart. The incorporation of these medications into a comprehensive treatment strategy underscores their role in optimizing cardiovascular health. It remains imperative for healthcare professionals to personalize prescriptions based on individual patient profiles, ensuring that the therapeutic benefits are maximized while mitigating potential side effects. The dynamic landscape of Cardiac Calcium Channel Blocker Therapy remains a driving force in advancing cardiovascular medicine and elevating the standard of care for individuals with heart-related conditions.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom